During oral arguments in Mayo v. Prometheus, justices question what standard to apply in assessing whether the correlation of a drug’s metabolites to proper dosage is patentable; ACLU petitions court to review Myriad gene patent case.
Supreme Court justices grappled with the standard to apply in determining whether a test that correlates a drug’s metabolites to proper dosage is patent-eligible during Dec. 7 oral arguments in Mayo Collaborative Services v. Prometheus Laboratories Inc.
The justices questioned Mayo’s contention that Prometheus’s patent simply covers a natural phenomenon. But they also asked whether the application...
PTC Therapeutics is continuing to supply its Duchenne muscular dystrophy treatment, Translarna, in some European markets, despite EU revocation of the drug’s conditional marketing authorization earlier this year.
The UK Health Research Authority’s latest three-year strategy sets ambitious targets to make research more transparent. One World Health Organization official believes the authority can go further by setting equally high standards for the timely reporting of clinical trial results.
Other authorities are expected to mirror the European Medicines Agency’s decision to lift the temporary restriction it placed on using Valneva’s chikungunya vaccine in people aged 65 years and older.
